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Abstract
Background: Recombinant KSAC and L110f are promising Leishmania vaccine candidates. Both antigens formulated in
stable emulsions (SE) with the natural TLR4 agonist MPLH and L110f with the synthetic TLR4 agonist GLA in SE protected
BALB/c mice against L. major infection following needle challenge. Considering the virulence of vector-transmitted
Leishmania infections, we vaccinated BALB/c mice with either KSAC+GLA-SE or L110f+GLA-SE to assess protection against L.
major transmitted via its vector Phlebotomus duboscqi.
Methods: Mice receiving the KSAC or L110f vaccines were challenged by needle or L. major-infected sand flies. Weekly
disease progression and terminal parasite loads were determined. Immunological responses to KSAC, L110f, or soluble
Leishmania antigen (SLA) were assessed throughout vaccination, three and twelve weeks after immunization, and one week
post-challenge.
Results: Following sand fly challenge, KSAC-vaccinated mice were protected while L110f-vaccinated animals showed partial
protection. Protection correlated with the ability of SLA to induce IFN-c-producing CD4
+CD62L
lowCCR7
low effector memory
T cells pre- and post-sand fly challenge.
Conclusions: This study demonstrates the protective efficacy of KSAC+GLA-SE against sand fly challenge; the importance of
vector-transmitted challenge in evaluating vaccine candidates against Leishmania infection; and the necessity of a rapid
potent Th1 response against Leishmania to attain true protection.
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Introduction
Leishmaniasis is a neglected disease endemic in 98 countries
with an estimated 350 million people at risk and an estimated
burden of 2,357,000 disability-adjusted life years [1]. Visceral
leishmaniasis is fatal if left untreated, and the morbidity and
stigma caused by cutaneous leishmaniasis is significant [2].
Current treatment is dependent on long-term therapy with toxic
drugs, most requiring parenteral administration and hospital
supervision.
A vaccine against leishmaniasis is feasible because infection with
certain species, including L. major, or exposure to live Leishmania
(leishmanization) leads to a long-term protection in humans
[3,4,5,6,7]. Unfortunately, there is no commercial vaccine
available for humans despite the presence of an extensive list of
vaccine candidates shown to be protective in various animal
models [8]. With the exception of two vaccine candidates, a
synthetic glycovaccine [9] and autoclaved L. major+CPG [10], all
Leishmania vaccines tested to date were challenged with needle
inoculation of the Leishmania parasite. L110f and KSAC, two
fusion polyproteins, in various combinations with appropriate
adjuvants were shown to confer strong protection against
cutaneous and visceral leishmaniasis in mice following conven-
tional needle challenge [11,12]. None of these vaccines were
challenged by infected sand fly bites, the natural route of
transmission. For protection against L. major, the L110f and
KSAC-containing vaccines were tested separately in susceptible
BALB/c mice followed by an infected sand fly challenge.
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study the immunology of leishmaniasis and the protective effect of
potential Leishmania vaccine candidates [13,14,15]. It has been
long established that protection from Leishmania parasites requires
the induction of a Th1 immune response [16,17,18]. BALB/c
mice produce a polarized Th2 type immune response against
Leishmania spp. and are used extensively to test Leishmania antigens
[19]. It has been hypothesized that protective antigen/adjuvant
formulations in this model system are good vaccine candidates
since they have to overcome the natural Th2 bias of this strain.
Recently, Peters et al. [20] demonstrated that transmission of
Leishmania parasites by sand fly bites generates a specific innate
immune response involving a sustained recruitment of neutrophils
that promotes parasite establishment. Additionally, the authors
demonstrated that vector transmission of Leishmania parasites can
abolish protection observed in vaccinated mice following needle
challenge [10].
In the current work, we use a natural sand fly challenge model
in BALB/c mice to test the immunogenicity and protective
efficacy of the two fusion proteins L110f and KSAC formulated
with GLA-SE against L. major transmitted by the bite of its natural
sand fly vector Phlebotomus duboscqi.
Materials and Methods
Animals
We used 6 to 8 week old female BALB/c mice (Charles River
Laboratories Inc). Phlebotomus duboscqi sand flies, Mali strain, were
reared at the LMVR, NIAID, NIH.
Ethics statement
All animal experimental procedures were reviewed and
approved by the National Institute of Allergy and Infectious
Diseases Animal Care and Use Committee under animal protocol
LMVR4E. The NIAID DIR Animal Care and Use program
complies with The Guide for the Care and Use of Laboratory
Animals and with the NIH OACU ARAC guidelines.
Parasites
We used the L. major V1 (MHOM/IL/80/Friedlin) strain for all
sand fly infections apart from that shown in supporting
information (Figure S1). In Figure S1, we used the WR 2885
strain, a recent field isolate that originated in Iraq and was typed at
the Walter Reed Army Institute of Research. Washed amastigotes
were counted and added to the blood meal for sand fly infection or
placed directly in culture for the generation of metacyclics for
needle challenge.
Production of recombinant KSAC, L110f and GLA-SE
KSAC and L110f recombinant proteins were prepared as
previously described [11,12,21] and mixed at the time of injection
with a stable emulsion (SE) formulation of the pure, synthetic
hexa-acylated TLR4 agonist glucopyranosyl lipid A (GLA) [22].
More than one lot of each antigen was used in experiments with a
residual endotoxin content ranging from 77 to 245 EU/mg
protein for L110f and from ,0.05 to 27 EU/mg protein for
KSAC.
Vaccination of mice
Mice were vaccinated subcutaneously (s.c.) in the base of tail,
three times at three week intervals with 100 ml containing 10 mgo f
antigen (KSAC or L110f) formulated with 20 mg of GLA-SE or
with GLA-SE alone.
Sand fly infection and transmission of L. major to
vaccinated mice
Blood containing 3610
6 L. major amastigotes/ml was used to
artificially feed sand flies as previously described [23]. Sand flies
were used for transmission 13–14 days post-Leishmania infection.
Three weeks (early challenge) or 12 weeks (delayed challenge) after
the last immunization, 10 infected sand flies were applied to a
single mouse ear for 2 hours in the dark.
Intradermal needle challenge with L. major parasites
Vaccinated animals were injected intradermally in the right ear
with 2610
3 purified L. major metacyclics in 10 ml PBS using a 27-
gauge needle.
Measurement of Leishmania cutaneous lesions
The thickness of ear lesions was recorded on a weekly basis
using a vernier caliper (Mitutoyo Corp.).
Parasite quantification by Real Time PCR
Parasite quantification was performed using JW11 and JW12
Leishmania-specific primers [24] as well as the 18S primers to
amplify a housekeeping gene as previously described [25].
Expression levels were normalized to 18S DNA and corrected
for the weight of the whole ear.
Antibody detection by ELISA
Subclass (IgG1 and IgG2a) responses were measured by ELISA
using Immulon4-Thermo plates coated overnight at 4uC with
L110f or KSAC (2 mg/ml). Diluted sera (1/100) were incubated
for 1 hour at 37uC. After washing, plates were incubated with
alkaline phosphatase-conjugated anti-mouse IgG1 or IgG2a
antibodies (BD Biosciences, San Jose, CA) (1/1000). The plates
were developed using alkaline phosphatase substrate (SIGMA).
The reaction was recorded after 10 minutes at 405 nm.
Author Summary
Leishmaniasis is a neglected disease caused by the
Leishmania parasite and transmitted by the bite of an
infective sand fly. Despite the importance of this disease
there is no vaccine available for humans. Studies have
shown that vector-transmitted infections are more viru-
lent, promoting parasite establishment and abrogating
protection observed against needle-injected parasites in
vaccinated mice. KSAC and L110f, derived from Leishman-
ia-based polyproteins, protected mice against the needle-
injected parasites. Here, we tested the two molecules for
their capacity to protect mice against cutaneous leish-
maniasis transmitted by an infective sand fly. Our results
show that KSAC, but not L110f, confers protection against
Leishmania transmitted by sand fly bites where protection
was correlated to a strong immune response to Leishmania
antigens by memory T cells before and after sand fly
transmission of the parasite. This is the first report of a
Leishmania-based vaccine that confers protection against a
virulent sand fly challenge. Our results support the
importance of screening Leishmania vaccine candidates
using infective sand flies before moving forward with the
costly steps of vaccine development.
KSAC Protects from Vector-Transmitted CL
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Three weeks after the last immunization or one week post-
challenge with infected sand fly bites, spleen cells were obtained as
previously described [11] and stimulated with soluble Leishmania
major antigen (SLA,100 mg/ml), KSAC (10 mg/ml) or L110f
(10 mg/ml). Supernatants were collected 72 hours after incubation
to evaluate cytokine production (IFN-c, IL-10 and IL-4) by ELISA
(BD Biosciences, San Diego, CA) according to the manufacturer’s
protocol.
Flow cytometry
Three weeks after the last immunization or one week post-
challenge with infected sand fly bites, 2610
6 splenocytes from
individual mice were cultured in complete RPMI medium in flat-
bottom 48-well plates with or without SLA (100 mg/mL), KSAC
(20 mg/ml) or L110f (20 mg/ml) at 37uCi n5 %C O 2 for 18 h.
Cells were incubated with Brefeldin A (BD Golgi Plug; BD
Pharmingen) during the last 4 h of culture, washed with PBS, and
blocked with anti-CD16/CD32 (BD Fc block, 2.4G2; BD
Pharmingen) for 30 minutes at 4uC. Cells were stained with the
fluorochrome-conjugated antibodies (BD Pharmingen and eBios-
ciences) PerCP-labeled anti-CD4 (RM4-5), APC-labeled anti-
TCR-b (H57-597), PECy7-labeled anti-CD62L (MEL-14), and
PE-labeled anti-CCR7 (4B12) for 30 minutes at 4uC, washed
twice, fixed and permeabilized with Cytofix/Cytoperm Plus (BD
Pharmingen), and stained with FITC-labeled anti-IFN-c (XMG
1.2). A minimum of 100,000 cells were acquired using a FACS
Calibur flow cytometer (BD Biosciences) and analyzed with the
Flow Jo software (Tree Star, Inc., Oregon).
Statistical analysis
A two-tailed unpaired Student’s t-test was used for statistical
analysis using the GraphPad software (GraphPad Software Inc.). P
values of 0.05 or less were considered significant.
Results
Induction of antibodies in mice vaccinated with KSAC
and L110f
Immunization of mice with KSAC+GLA-SE induced a robust
antibody response following the first immunization and afterwards
maintaining a positive IgG2a:IgG1 ratio (Fig. 1 A, B). In contrast,
L110f+GLA-SE induced a weaker overall antibody response that
was biased towards IgG1 antibody production (Fig. 1A, B).
Immunization with KSAC+GLA-SE protects against
vector-transmitted Leishmania major (Friedlin V1)
infection
Mice vaccinated with KSAC+GLA-SE or L110f+GLA-SE
controlled a needle-challenge infection for at least eight weeks,
whereas mice receiving GLA-SE alone did not (P,0.001,
Figure 2A). Animals immunized with either vaccine also controlled
L. major infection post-sand fly challenge through 6 weeks,
although the level of protection with the L110f-containing vaccine
was reproducibly lower than that for the KSAC-containing
vaccine (Figure 2C). KSAC+GLA-SE, but not L110f+GLA-SLE
immunized mice displayed significant protection up to the final 8
week time point (Figure 2C). The parasite burden assessed eight
weeks after challenge with either needle or infected sand flies
supports the pathology data (Figure 2B, D). Following needle
challenge, the parasite number was significantly decreased in
KSAC+GLA-SE (P,0.01) and L110f+GLA-SE (P,0.05) com-
pared to GLA-SE immunized mice (Figure 2B). Following sand
fly-challenge, only KSAC+GLA-SE immunized mice showed a
significant reduction of parasite number (P,0.01) compared to
GLA-SE immunized mice (Figure 2D). The number of parasites in
L110f+GLA-SE immunized mice were intermediate, but showed
no significant difference from controls (Figure 2D).
Effector memory T cell responses in KSAC+GLA-SE and
L110f+GLA-SE immunized mice pre- and post- challenge
with L. major (Friedlin V1)-infected sand flies
KSAC+GLA-SE vaccination induced the production of KSAC-
specific IFN-c
+ CD4
+ T cells, and the relative size of this cell
fraction was maintained after a challenge with L. major-infected
sand flies (Fig. 3A). In contrast, CD4
+ T cells of mice immunized
with L110f+GLA-SE and stimulated with L110f produced IFN-c
only after the mice were challenged with infected flies (Figure 3B).
Importantly, CD4
+ T cells from KSAC+GLA-SE-immunized
mice produced IFN-c following stimulation with SLA, while cells
from animals immunized with L110f+GLA-SE were non-respon-
sive (Figure 3C). Before sand fly challenge the percentage of
CD4
+CD62L
lowCCR7
low effector memory T cells producing IFN-
c was greater in KSAC-immunized mice stimulated ex vivo with
KSAC compared to GLA-SE alone or L110f-immunized mice
stimulated with L110f (Figure 3D, KSAC and L110f panels). Of
note, the percentage of L110f-specific effector memory IFN-
c
+CD4
+ T cells from L110f+GLA-SE -immunized mice was
greater after sand fly challenge than either the KSAC+GLA-SE or
GLA-SE control groups stimulated with the appropriate antigens.
Nevertheless, SLA induced a greater percentage of IFN-c
+ effector
memory T cells from KSAC+GLA-SE-immunized mice than from
either L110f+GLA-SE or the control GLA-SE groups before and
after sand fly challenge (Fig. 3D, SLA panel).
Antigen-specific IFN-c predominates over IL-10 in
vaccinated mice challenged with L. major (Friedlin V1)-
infected sand flies
Mice vaccinated with KSAC+GLA-SE produced a high level of
antigen-specific IFN-c following ex vivo stimulation with SLA or
KSAC both pre- and post-challenge with infected flies (Figure 4A).
Prior to infected sand fly challenge, IFN-c production was 23 ng/
ml and 62 ng/ml following stimulation with SLA and KSAC,
respectively (Figure 4A). This increased 8 and 3 fold when tested
one week post-challenge, reaching 194 ng/ml and 212 ng/ml
following stimulation with SLA and KSAC, respectively
(Figure 4A). A distinctly different response was observed in
L110f+GLA-SE-immunized mice where pre-challenge IFN-c
production was low to undetectable after stimulation with either
SLA or L110f (Figure 4A), whereas IFN-c was readily detectable
after challenge with infected flies. Post-challenge, 57 ng/ml of
IFN-c and 222 ng/ml were produced in L110f-immunized mice
in response to SLA and L110f, respectively (Figure 4A). Overall,
antigen-stimulated splenocytes produced a low level of IL-10
compared to the relatively high concentration of IFN-c produced
(Figure 4A, B). The highest levels of IL-10 were produced by
spleen cells of KSAC-immunized mice pre-challenge with infected
flies (.3.3 ng/ml and 1.7 ng/ml with SLA and KSAC stimula-
tion, respectively) compared to post-challenge levels (Figure 4A);
post-challenge levels were reduced to ,1 ng/ml following
stimulation with either SLA or KSAC (Figure 4A). Similar to
IFN-c, IL-10 was not detectable in L110f+GLA-SE immunized
mice pre-challenge and produced 1.2 and 2.4 ng/ml IL-10 after
stimulation with SLA and L110f, respectively, after sand fly
challenge (Figure 4A). The ratio of IFN-c:IL-10 highlight the
dominance of IFN-c over IL-10 in mice vaccinated with either
KSAC Protects from Vector-Transmitted CL
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production in response to immunization with GLA-SE alone
(Figure 4C).
Immunization with KSAC+GLA-SE confers long-term
protection against vector-transmitted Leishmania major
(Friedlin V1) infection
Mice vaccinated with KSAC+GLA-SE maintained a positive
KSAC-specific IgG2a:IgG1 ratio for at least 12 weeks after the
final vaccination (Fig. 5A). These mice were protected against a
delayed challenge with L. major-infected sand flies, maintaining
significantly smaller lesions (P,0.05 to ,0.001) compared to mice
vaccinated with GLA-SE alone (Figure 5B). In this delayed
challenge, mice vaccinated with L110f+GLA-SE exhibited an
almost equal IgG2a:IgG1 ratio lower than that of KSAC+GLA-SE
vaccinated mice (Figure 5A), possibly reflecting a slower and less
dramatic shift to a Th1 response. These mice were only partially
protected against L. major transmitted by infected sand flies
(Figure 5B). The long-term protection conferred by vaccination
with KSAC is reflected by the absence of disease pathology up to
five weeks post-challenge compared to GLA-SE-vaccinated mice
and to a lesser degree to the partially protected L110f+GLA-SE-
vaccinated mice (Figure 5B panels).
To assess the relevance of the parasite strain used in challenge,
we carried out a preliminary experiment using a recent field isolate
of L. major (WR-2885), a strain kindly provided to us by Dr. Edgar
Rowton, Walter Reed Army Institute of Research, Washington,
D.C., to test the level of protection provided by KSAC or L110f
vaccines. KSAC-immunized mice were protected while L110f-
immuinized mice lost the partial protection displayed against the
Friedlin V1 laboratory attenuated parasite strain (Figure S1).
Discussion
The Leishmania-derived polyproteinsL110f andKSAC havebeen
extensively studied. L110f or its first generation antigen Leish-111f
(equivalent to the clinical antigen LEISH-F1) and KSAC elicited
protective immunity against L. major as well as L. infantum in rodent
models of infection initiated by needle challenge [11,12,26,27].
Both antigens are well-defined and used in formulation with MPLH-
SE or GLA-SE, adjuvants suitable for human use.
Figure 1. Antibody responses induced by vaccination with KSAC+GLA-SE or L110f+GLA-SE. BALB/c mice were vaccinated by the
subcutaneous route three times every three weeks with either 20 mg adjuvant alone (GLA-SE), 10 mg KSAC+20 mg GLA-SE, or 10 mg L110f+20 mg GLA-
SE. Serum was obtained one day before each immunization and 20 days after the last immunization. (A) KSAC- and L110f-specific IgG1 and IgG2a
antibody levels in mice vaccinated with the respective antigen. (B) Ratio of antigen-specific IgG2a:IgG1 levels in mice vaccinated with KSAC+GLA-SE
or L110f+GLA-SE. The OD values are presented after subtraction of the OD value of mice vaccinated with GLA-SE alone. Ten mice were used in each
group. Data are representative of two independent experiments.
doi:10.1371/journal.pntd.0001610.g001
KSAC Protects from Vector-Transmitted CL
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used by Bertholet et al. [11] for L110f and Goto et al. [12] for
KSAC with the exception of the exclusive use of a stable emulsion
containing GLA, a synthetic glucopyranosyl lipid A molecule
similar to the naturally derived MPLH [21]. The objective was to
test whether vaccination of mice with either antigen is equally
protective against challenge by L. major-infected P. duboscqi sand
flies. This work is relevant to the value of these antigens as
vaccines; particularly following findings by Peters et al. [20]
demonstrating that parasite transmission by vector bite induces a
specific innate immune response, which promotes the establish-
ment of L. major infection. The authors went further to
demonstrate that the virulence of vector-transmitted infections
overcomes the protection observed against a needle challenge of
vaccinated mice [10].
When BALB/c mice were challenged with infected sand flies,
the KSAC+GLA-SE-vaccinated animals were protected from
infection by both a laboratory-maintained parasite and a more
Figure 2. Vaccination of mice with KSAC+GLA-SE provides better protection from vector-transmitted L. major than does L110f+GLA-
SE. BALB/c mice were challenged three weeks after the last vaccination in one ear with a needle injection of 2000 purified L. major metacyclics or
exposed in one ear to bites of 10 L. major-infected sand flies (P. duboscqi). (A and C) Ear lesion thickness was measured in mice vaccinated with GLA-
SE (N), KSAC+GLA-SE (&), or L110f+GLA-SE (m) and challenged with needle (A) or infected-sand fly bites (C). Panels show representative ears of
vaccinated mice eight weeks after challenge. (B and D) Parasite load determined by Real-Time PCR eight weeks after challenge with needle (B) or
infected-sand fly bites (D). Statistical significance was determined for KSAC+GLA-SE- or L110f+GLA-SE-vaccinated mice compared to the GLA-SE-
vaccinated mice using a two-tailed, unpaired Student’s t-test (*, p,0.05; **, p,0.01; ***, p,0.001). Five to seven mice were used in each group. Data
are representative of three independent experiments.
doi:10.1371/journal.pntd.0001610.g002
KSAC Protects from Vector-Transmitted CL
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(WR-2885). The partial protection observed in L110f-vaccinated
mice following either needle or fly challenge with the Friedlin-V1
strain was abrogated when the mice were challenged with sand
flies carrying the virulent WR-2885 strain. These data are
consistent with the reported increase in virulence of a vector-
transmitted infection and emphasize the need to test promising
vaccines in vector-transmission models [10,20]. Additionally, the
data draw attention to the importance of the virulence of the
parasite strain used in challenge experiments particularly for
vaccine studies.
It is important to point out that the clinical forms of L111f and
L110f (LEISH-F1 and LEISH-F2, respectively) delivered with
MPLH-SE were safe and immunogenic in healthy subjects with
and without histories of previous infection with L. donovani [28].
Additionally, LEISH-F1 had some therapeutic value in patients
with mucosal and cutaneous leishmaniasis where it appeared to
shorten time to cure when used with chemotherapy [29,30]. Both
Leish-111f and Leish-110f demonstrated therapeutic efficacy in
dogs with canine leishmaniasis [31,32]. Therefore, L110f should
not be overlooked as a valuable vaccine in our fight against
leishmaniasis.
Based on present and previous data [12] KSAC and GLA-SE
used together show considerable promise as a preventive vaccine.
Vaccinated mice were mostly pathology-free after challenge with
either the Friedlin V1 or WR2885 L. major strains. Additionally,
vaccinated mice were protected in a delayed challenge 12 weeks
after the last vaccination using infected sand flies, indicative of the
generation of long-lasting immunity. Protection was associated with
a consistently positive IgG2a:IgG1 ratio for KSAC. Interestingly, in
L110f-immunized mice that were partially protected, this ratio
fluctuated from negative to neutral at 62 days and 12 weeks post-
Figure 3. IFN-c-producing CD4+ T cells before and after challenge with L. major -infected sand flies. Mice were vaccinated
subcutaneously with 10 mg KSAC+20 mg GLA-SE, 10 mg L110f+20 mg GLA-SE, or 20 mg GLA-SE alone. Splenocytes were analyzed three weeks after the
last immunization (Pre-challenge) or one week Post challenge with L. major. Splenocytes gated on TCRb
+CD4
+ T cells for the percentage of IFN-c
+
CD4
+ T cells produced after antigen stimulation (A–C). (A) Splenocytes from KSAC+GLA-SE- or GLA-SE-vaccinated mice stimulated with 20 mg
recombinant KSAC in vitro; (B) Splenocytes from L110f+GLA-SE- or GLA-SE-vaccinated mice stimulated with 20 mg recombinant L110f; or (C)
Splenocytes from KSAC+GLA-SE-, L110f+GLA-SE-, or GLA-SE-vaccinated mice stimulated with 100 mg SLA in vitro. (D) Splenocytes gated on
TCRb
+CD4
+CD62L
lowCCR7
low T cell population for the percentage of effector memory CD4
+ splenic T cells in mice vaccinated with GLA-SE,
KSAC+GLA-SE or L110f+GLA-SE after stimulation with either KSAC, L110f or SLA. Three mice were used per group. Data are representative of two
independent experiments.
doi:10.1371/journal.pntd.0001610.g003
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www.plosntds.org 6 April 2012 | Volume 6 | Issue 4 | e1610Figure 4. Cytokine production before and after challenge of mice with L. major -infected sand flies. Mice were vaccinated
subcutaneously with 10 mg KSAC+20 mg GLA-SE, 10 mg L110f+20 mg GLA-SE, or 20 mg GLA-SE alone. IFN-c (A) or IL-10 (B) production was measured
by ELISA after in vitro stimulation of spleen cells with 100 mg SLA, 10 mg recombinant KSAC, or 10 mg recombinant L110f. Results are from
stimulations performed at two time points: three weeks after the last immunization and one week post challenge. (C) Ratio of IFN-c: IL-10 in
vaccinated mice. Mean and SEM of three mice per group. Data are representative of two independent experiments. nd=none detected.
doi:10.1371/journal.pntd.0001610.g004
Figure 5. Vaccination with KSAC+GLA-SE confers long-term protection against L. major -infected P. duboscqi sand flies. Mice were
vaccinated subcutaneously with 10 mg KSAC+20 mg GLA-SE, 10 mg L110f+20 mg GLA-SE, or 20 mg GLA-SE alone. (A) The ratio of IgG2a:IgG1 was
determined 12 weeks after the last vaccination and prior to the delayed challenge. (B) Lesion thickness in mice vaccinated with KSAC+GLA-SE (&),
L110f+GLA-SE (m), or GLA-SE alone (N) and challenged with L. major-infected sand flies in the right ear 12 weeks (delayed challenge) after the last
immunization. Panels show representative ears of vaccinated mice five weeks after challenge. (C) Parasite load determined by Real-Time PCR five
weeks after challenge with infected-sand fly bites. Statistical significance was determined for mice vaccinated with KSAC+GLA-SE or L110f+GLA-SE
compared to the adjuvant group using a two-tailed unpaired Student’s t-test (*, p,0.05; **, p,0.01; ***, p,0.001). Ten mice were used per group.
Data are representative of two independent experiments.
doi:10.1371/journal.pntd.0001610.g005
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stabilization of antibody levels over time and further emphasizes the
importance of testing the efficacy of the immune response to a
vaccine in a delayed challenge. Of note, both KSAC and L110f
generated a Th1-biased cell-mediated immunity. This was
demonstrated by the predominant antigen-specific IFN-c response
(relative to the IL-10 response) of spleen cells from vaccinated mice
one week post-challenge. However, L110f-vaccinated mice did not
mount an immune response to SLA nor to pre-challenge
stimulation of spleen cells with antigen. This finding is distinct
from that of Bertholet et al. [11] where they demonstrated a
balanced IgG2a/IgG1 responseto L110f plus GLA-SEorMPL-SE,
a sizable induction of CD4
+CD44
high IFN-c
+ cells, and good
protection with both vaccines when challenged by needle. We
cannot account with certaintyfor the apparent discrepancy between
our immunogenicity results with L110f+GLA-SE and those of
Bertholet et al. [11] and other reports using L111f/L110f+GLA-SE
or +MPL-SE [26,33,34]. One difference between these studies and
ours is the time chosen for pre-challenge analysis. In any case, the
reduced protection we observed against the two L. major strains
tested using L110f+GLA-SE correlate well with the relatively weak
shift to a Th1 response that was observed after vaccination, but
before parasite challenge. In contrast, splenocytes from KSAC+-
GLA-SE-vaccinated mice responded well to stimulation with
antigen and, more importantly, to stimulation with SLA pre- and
post- challenge by infected bites. KSAC-immunized mice generate
a pool of effector memory CD4
+IFN-c
+ T cells specific to KSAC
that was efficientlystimulated with SLAboth beforeand aftera sand
fly challenge. These results suggest that the rate and magnitude of
the immune response are important for the generation of protection
against a virulent sand fly-transmitted infection. Additionally, the
observed differences in the protective effect of L110f and KSAC,
both formulated with GLA-SE, against vector-challenge may be
related to other factors such as antigenicity, accessibility or amount
of the natural proteins making up these polypeptides.
Recent studies (S. Bertholet, personal communication) have
shown that lower doses of adjuvant (GLA-SE) are more efficient at
inducing long-lived CD4 memory responses, especially with L110f
as an antigen (data not shown). This could indicate that optimal
adjuvant doses vary for different antigens and might need to be
titrated accordingly. The KSAC results reported here demonstrate
that the synthetic TLR4 agonist GLA can be a powerful tool to
direct a shift from Th2 to a Th1-type response, necessary to
combat a vector-transmitted L. major infection.
In summary, the BALB/c mouse model was used in our
experiments because it is especially susceptible to L. major infection
as a result of its genetically determined Th2 immune response. We
observed that immunization with KSAC in combination with the
TLR4 agonist GLA in stable emulsion overcomes the Th2 bias of
BALB/c mice, generating a robust, cell-mediated Th1 immune
response inthesemice. Thisimmunological activationresults insolid
protection against vector-transmitted L. major infection, protection
that is comparable to the one observed following needle challenge.
As anticipated, immunization conditions (using L110f+GLA-SE)
that produced a more modest immune response with a less dramatic
shift from a Th2 to a Th1 response was less protective.
KSAC, a defined Leishmania-based vaccine candidate shows
protection against a sand fly challenge, and this protection was
produced in combination with the clinically viable adjuvant GLA-
SE. With these encouraging results, more work is needed to test
the protective nature of these vaccine components in more
relevant models of cutaneous leishmaniasis.
Supporting Information
Figure S1 Protection in KSAC+GLA-SE-vaccinated mice
following sand fly challenge with a recent L. major
isolate. Mice were vaccinated subcutaneously with 10 mg
KSAC+20 mg GLA-SE, 10 mg L110f+20 mg GLA-SE or 20 mg
GLA-SE alone and challenged 12 weeks later (delayed challenge)
with sand flies infected with a highly virulent strain of L. major
recently isolated from a human lesion. (A) Lesion thickness in mice
vaccinated with KSAC+GLA-SE (&), L110f+GLA-SE (m), or
GLA-SE alone (N). (#) Mice were euthanized 4 weeks post-
challenge due to severity of the lesions. (B) Panels showing
representative lesions on ears of mice vaccinated with GLA-SE
(1), KSAC+GLA-SE (2), or L110f+GLA-SE (3) three, four, and five
weeks post-delayedchallenge with L. major-infected sand flybites.(Y)
Five weeks post-challenge, only one out of 5 mice showed a small
ulcerated lesion in the group vaccinated with KSAC+GLA-SE.
Statistical significance was determined for KSAC+GLA-SE- or
L110f+GLA-SE-vaccinated mice compared to the adjuvant group
using a two-tailed unpaired Student’s t-test (*, p,0.05). Five mice
were used per group. The experiment was carried out once.
(TIFF)
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